▲ Bullish for Glenmark Pharmaceuticals
Glenmark expects innovative drugs to drive higher revenue share: CMD Glenn Saldanha
The brief
- Glenmark expects innovative drugs to contribute a higher share of revenue as it shifts beyond generics
- Glenmark’s shift beyond generics could reshape its revenue mix for Indian pharma investors
- Markets snap eight-week losing streak; Financials lead, Healthcare and IT drag
- Hospital stocks face valuation reset risk as price-cap fears expose margin pressure
- AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
- Hospital stocks: can strong demand offset regulatory risks?
- Why the stock market fell for 8th straight week, its longest losing streak in 25 years